Sex differences in the outcomes of stent implantation in mini-swine model

Figures

• 

  Fig 1. Neointima area at each follow-up timing. (A) Single BMS implantation, (B) Overlapped BMS implantation, (C) Single DES implantation, (D) Overlapped DES implantation. No significant differences between female and male groups were observed at any following timings.

• 

  Fig 2. Distribution of neointima area. (A) Single BMS implantation, (B) Overlapped BMS implantation, (C) Single DES implantation, (D) Overlapped DES implantation. No significant differences between female and male groups were observed.

• 

  Fig 3. Luminal occlusion at each follow-up timing. (A) Single BMS implantation, (B) Overlapped BMS implantation, (C) Single DES implantation, (D) Overlapped DES implantation. Higher luminal occlusion with statistically significant difference were observed 30 days after overlapped BMS implantation in the male group (B), 365 days after single DES implantation in the female group (C), and 180 days after overlapped DES implantation (D).

• 

  Fig 4. Distribution of luminal occlusion. (A) Single BMS implantation, (B) Overlapped BMS implantation, (C) Single DES implantation, (D) Overlapped DES implantation. No significant differences between female and male groups were observed.

• 

  Fig 5. Injury score at each follow-up timing. (A) Single BMS implantation, (B) Overlapped BMS implantation, (C) Single DES implantation, (D) Overlapped DES implantation. Higher injury scores were observed in the female group 180 days after single BMS implantation (A), 365 days after single DES implantation (C), and 180 days after overlapped DES implantation (D).

• 

  Fig 6. Adventitial fibrosis score at each follow-up timing. (A) Single BMS implantation, (B) Overlapped BMS implantation, (C) Single DES implantation, (D) Overlapped DES implantation. Higher adventitial fibrosis scores were observed 180 days after single BMS implantation in the female group (A), 365 days after single BMS implantation in the male group (A), 30 days after overlapped BMS implantation in the male group (B), 30 and 90 days after single DES implantation in the male group (C), and 365 days after single DES implantation in the female group (C).

• 

  Fig 7. Inflammation score at each follow-up timing. (A) Single BMS implantation, (B) Overlapped BMS implantation, (C) Single DES implantation, (D) Overlapped DES implantation. A higher inflammation score with statistical significance was observed in the male group 365 days after single BMS implantation (A).

• 

  Fig 8. Neointimal fibrin score at each follow-up timing. (A) Single BMS implantation, (B) Overlapped BMS implantation, (C) Single DES implantation, (D) Overlapped DES implantation. Black lines in the male group at 90, 180, and 365 days after single BMS implantation and at 365 days after single DES implantation, and in the female group at 90 days after single BMS implantation, at 90 days after overlapped BMS implantation, and at 365 days after single DES implantation indicate that the neointimal fibrin scores were 0. A higher neointimal fibrin score was observed in male group 30 and 180 days after single DES implantation (C), and 90 days after overlapped DES implantation (D). The statistically significant decreases over time were observed in the female group after single and overlapped DES implantation (C, D).